| Name | Ribostamycin sulfate |
| Description | Ribostamycin sulfate (Vistamycin sulfate) , an aminoglycoside antibiotic, contains a neutral sugar moiety and is produced by Streptomyces ribosome. |
| In vitro | Ribostamycin, as an intermediate in the biosynthesis of neomycin, can inhibit the chaperone activity of protein disulfide isomerase (PDI) but does not inhibit its isomerase activity. At a concentration of 256 µg/mL, it exhibits almost no toxicity to HUVEC cells. |
| In vivo | Compared to other antibiotics, Ribostamycin (400 mg/kg/day) causes the lowest ototoxicity, as its drug concentration in the inner ear fluid of guinea pigs is relatively low. Ribostamycin exhibits the least ototoxicity to the cochlea and vestibular organs of guinea pigs. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10%DMSO + 90% Saline : 100 mg/mL (180.98 mM), Sonication is recommended.
DMSO : 1000 mg/mL (1809.79 mM), Sonication is recommended.
PBS : 100 mg/mL (180.98 mM), Sonication is recommended.
H2O : 100 mg/mL (180.98 mM), Sonication is recommended.
|
| Keywords | Vistamycin Sulfate | Vistamycin | Ribostamycin sulfate | Ribostamycin | Inhibitor | inhibit | Bacterial | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | Drug Repurposing Compound Library | Saccharide and Glycoside Natural Product Library | Natural Product Library | Microbial Natural Product Library | NO PAINS Compound Library | Natural Product Library for HTS | Immunology/Inflammation Compound Library | Anti-infective Natural Product Library | Bioactive Compounds Library Max | NMPA-Approved Drug Library |
United States
